Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06153693 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
A Phase 3 study of Hypertension, sponsored by Mineralys Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,083
- Enrollment target
- 20
- Study locations
NCT06153693: Completed Phase 3 study of Hypertension, sponsored by Mineralys Therapeutics.
NCT06153693 is a Phase 3 study of Hypertension that has completed, run by Mineralys Therapeutics. The registered enrollment target is 1,083 participants, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06153693, a Phase 3 study of Hypertension, has completed, sponsored by Mineralys Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,083 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resistant hypertension taking between 2 and 5 anti-hypertensive (AHT) medications.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG lorundrostat Dose 1
- DRUG lorundrostat Dose 2
Study Locations (20)
California
- Entertainment Medical Group, Inc. - Beverly Hills
- Amicis Research Center - Granada Hills - Granada Hills
- Amicis Research Center - Northridge - Granada Hills
- Marvel Clinical Research, LLC - Huntington Beach
- Amicis Research Center - Northridge
- Pasadena Clinical Trials - Pasadena
- Empire Clinical Research (ECR) - Pomona
- Clinical Trials Research (CTR) - Sacramento - Sacramento
- North America Research Institute - San Dimas
- Amicis Research Center - Valencia - Valencia
Alabama
- Advanced Cardiovascular, LLC - Alexander City Office - Alexander City
- Central Research Associates, Inc - Birmingham
- Cardiology, P.C. - Birmingham
- Synexus (Radiant Research, Inc) - Alabama - Simon Williamson Clinic Location - Birmingham
- G & L Research LLC - Foley - Foley
- Accel Research Sites (ARS) - Birmingham Clinical Research Unit - Vestavia Hills
Connecticut
- CMR of Greater New Haven - Hamden
- Chase Medical Research, LLC - Hamden - Waterbury
Arizona
- Del Sol Research - Tucson
Florida
- Indago Research and Health Center - Hialeah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,083 participants |
| Start Date | 2023-11-22 |
| Est. Completion | 2025-01-24 |
| Phase | Phase 3 |
What the finished NCT06153693 record still lists
NCT06153693 is an interventional study that assigns participants to a tested intervention. Its 1,083 participants enrollment target places it among the larger protocols in the corpus, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06153693 names 20 study sites across 5 states, led by California, Alabama, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06153693 about?
NCT06153693 is a clinical study titled "Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension". This is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resistant hypertension taking between 2 and 5 anti-hypertensive (AHT) medications.
What is the current status of trial NCT06153693?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,083 participants. The study started on 2023-11-22. Estimated completion is 2025-01-24.
What conditions does trial NCT06153693 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT06153693?
The interventions under investigation include: Placebo (DRUG), lorundrostat Dose 1 (DRUG), lorundrostat Dose 2 (DRUG).
Who is sponsoring clinical trial NCT06153693?
This trial is sponsored by Mineralys Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06153693 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06153693's enrollment target sits among peer trials
1,083 62nd of 470 higher than 409 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06074068 · 1,080 participants · NA
Father-Focused Intervention for Reducing Family Violence and Symptoms in Children
- NCT07213804 · 1,080 participants · Phase 3
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
- NCT06671483 · 1,088 participants · Phase 3
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
- NCT07084883 · 1,076 participants
Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI